Ephedrine Compositions and Methods
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 16/749,378, filed Jan 22, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,869,845 | Ephedrine Compositions and Methods In force · High confidence | Nevakar Injectables Inc. | In force | High confidence | ||
| US 11,491,121 | Ephedrine Compositions and Methods In force · High confidence | Nevakar Injectables Inc. | In force | High confidence | ||
| US 12,029,710 | Ephedrine Compositions and Methods In force · Medium confidence | Nevakar Injectables Inc. | In force | Medium confidence | ||
| Application 18/676,168 | Ephedrine Compositions and Methods Pending Not granted | Nevakar Injectables Inc. | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Nevakar Injectables Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.